CTOs on the Move

Imago BioSciences

www.imagobio.com

 
Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Imago BioSciences raised $10M on 03/21/2019
Imago BioSciences raised $80M on 11/19/2020

Similar Companies

Brampton Cosmetic Surgery

Brampton Cosmetic Surgery is a Brampton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prime Medicine

Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations.

Aquascience Research Group

Aquascience Research Group is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

iBio

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio`s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It`s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.

Bioverativ

Bioverativ Inc. is an American multinational biotechnology that specializes in the discovery, development, and delivery of therapies for the treatment of haemophilia.